Induction of Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury in Mice
January 19th, 2022
8.3K views
Here we describe a simple and reproducible method that can induce myocardial infarction or myocardial ischemia-reperfusion injury in mice by precision ligation of the left anterior descending coronary artery through micromanipulation.
Overview
This study describes a customizable method to create a myocardial function model in mice by precision ligation of the left anterior descending coronary artery through micromanipulation. This protocol reduces procedure duration, ensures controllable infarct size, and improves mouse survival.
Key Study Components
Area of Science
- Cardiovascular research
- Mouse models of myocardial infarction
- Surgical techniques in animal studies
Background
- Myocardial infarction is a critical condition affecting heart function.
- Existing methods for inducing myocardial injury can be complex and time-consuming.
- Improving surgical protocols can enhance animal welfare and research outcomes.
- Precision ligation techniques offer a reproducible approach for inducing myocardial injury.
Purpose of Study
- To develop a simple and reproducible method for inducing myocardial infarction in mice.
- To ensure controllable infarct size and improve survival rates.
- To streamline the surgical procedure for better efficiency.
Methods Used
- Use of a rectangular operating table (OT) with a heating pad pre-warmed to 37 degrees Celsius.
- Disinfection of the surgical area with ultraviolet light and 70% alcohol.
- Positioning the mouse supine with gauze under the head to prevent overheating.
- Application of ophthalmic ointment to protect the eyes during the procedure.
Main Results
- The method allows for precise control over infarct size.
- Improved survival rates of mice post-surgery.
- Reduced duration of the surgical procedure.
- Enhanced reproducibility of myocardial injury models.
Conclusions
- This protocol provides a reliable method for inducing myocardial infarction in mice.
- It offers significant improvements in efficiency and animal welfare.
- The approach can be beneficial for future cardiovascular research.
Frequently Asked Questions
What is the significance of this study?
This study presents a reproducible method for inducing myocardial infarction in mice, which is crucial for cardiovascular research.
How does this method improve mouse survival?
By reducing the complexity and duration of the surgical procedure, the method enhances overall mouse welfare and survival rates.
What are the key components of the surgical setup?
The setup includes a pre-warmed operating table, disinfection protocols, and proper positioning of the mouse.
Can this method be customized?
Yes, the method is designed to be customizable based on specific research needs.
What are the implications for future research?
This method can facilitate more efficient and ethical research in myocardial infarction studies.
Is this technique applicable to other animal models?
While this study focuses on mice, the principles may be adapted for other small animal models.
Executive Industry Relevance
Robust in vivo models of myocardial infarction and ischemia-reperfusion injury are essential for early-stage cardiovascular drug discovery and mechanistic de-risking. This protocol enables precise, reproducible induction of cardiac injury in mice, supporting quantitative assessment of candidate interventions and translational biomarker development. Consistent infarct size and functional readouts enhance predictive confidence at the preclinical inflection point.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses targeting myocardial injury and repair pathways.
- Supports functional validation of cardiac targets through controlled infarct induction.
- Facilitates mechanistic de-risking by providing reproducible injury models for pathway analysis.
Screening & Assay Development
- Prepares validated in vivo systems for downstream efficacy and safety screening of candidate compounds.
- Standardizes infarct size and injury metrics, improving assay reproducibility and quantitative output.
- Enables reliable evaluation of intervention effects on cardiac function and injury biomarkers.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints such as cardiac troponin T and echocardiographic function.
- Provides continuity from discovery through preclinical validation using clinically translatable readouts.
- Supports risk-adjusted advancement decisions based on quantitative injury and recovery metrics.
Pipeline & Workflow Integration
This model integrates into the discovery-to-preclinical continuum, enabling hypothesis testing, lead evaluation, and translational biomarker alignment for cardiovascular portfolios.
- Discovery Biology: Supports null hypothesis testing and pathway clarification in cardiac injury mechanisms.
- Screening: Delivers reproducible, quantitative infarct and function data for compound triage.
- Analytics: Provides ECG, serum cTnT, and infarct size measurements for robust statistical comparison.
- Translational Research: Aligns preclinical endpoints with clinical biomarkers for improved predictive value.
- Enterprise Reuse: Offers a standardized, scalable platform for repeated use across cardiovascular programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac target validation.
- Operational Value: Enhances reproducibility, standardization, and scalability of in vivo cardiac injury models.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by enabling robust preclinical evaluation.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of cardiovascular assets.
Implementation Considerations
- Requires surgical expertise in micro-manipulation and small animal anesthesia.
- Needs access to ECG, echocardiography, and biochemical assay infrastructure.
- Demands rigorous cross-team standardization of surgical and analytical procedures.
- Adaptation to other rodent models may require protocol optimization.
- Limitations include technical variability and the need for consistent operator training.
Biopharma FAQs
Why does null hypothesis testing matter for LAD ligation models?
Null hypothesis testing in LAD ligation models enables objective evaluation of candidate interventions by comparing injury and recovery metrics against control groups. This approach supports rigorous target validation and reduces the risk of false-positive findings in early discovery. Quantitative endpoints such as cTnT and infarct size provide statistical power for decision-making.
How does independent variable isolation fit myocardial injury induction?
Isolating variables such as ligation position and ischemia duration ensures that observed effects on cardiac injury are attributable to the intervention under study. This precision supports reproducibility and mechanistic clarity, which are critical for advancing candidates through the discovery pipeline.
What do quantitative cTnT and infarct size measurements enable?
Quantitative measurement of serum cTnT and infarct size enables robust assessment of myocardial injury severity and intervention efficacy. These outputs facilitate cross-study comparisons and support translational alignment with clinical biomarkers.
Why are replication requirements critical for cross-functional teams?
Replication of myocardial injury models across operators and sites ensures data reliability and supports cross-functional collaboration in drug discovery. Consistent protocols and standardized readouts are essential for integrating findings into portfolio-level decisions.
What statistical analysis capabilities are needed before preclinical use?
Statistical analysis of ECG, cTnT, and infarct size data is required to validate model consistency and intervention effects. Teams must establish thresholds for significance and reproducibility before implementing findings in preclinical advancement decisions.
